Madrigal Pharmaceuticals (MDGL) Liabilities and Shareholders Equity (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $1.2 billion in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 23.15% year-over-year to $1.2 billion in Q1 2026; TTM through Mar 2026 was $4.9 billion, a 15.5% increase from a year earlier, with the FY2025 full-year figure at $1.3 billion, up 20.85% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $1.2 billion, down from $1.3 billion in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for MDGL reached as high as $1.4 billion in Q3 2025 and fell as low as $158.6 million in Q3 2022.
• Historically, Liabilities and Shareholders Equity has averaged $743.1 million across 5 years, with a median of $996.6 million in 2025.
• Across the five-year window, Liabilities and Shareholders Equity sank 47.93% in 2022 and surged 351.02% in 2024, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $362.6 million in 2022, then surged by 76.67% to $640.5 million in 2023, then surged by 62.71% to $1.0 billion in 2024, then climbed by 20.85% to $1.3 billion in 2025, then decreased by 2.56% to $1.2 billion in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $1.2 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.4 billion in Q3 2025.